Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity
Abstract The immunomodulation of the tumor microenvironment is critical for effective cancer immunotherapy, particularly for tumors that exhibit limited responses to conventional treatments. However, current immune agonists developed for tumor immunomodulation face several challenges, such as poor i...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202414110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179333500436480 |
|---|---|
| author | Huilan He Liang Liu Yun Zheng Jinlong Ji Li Cao Chunlian Ye Yu Sun Ying Zhang Zhiyuan Zhong |
| author_facet | Huilan He Liang Liu Yun Zheng Jinlong Ji Li Cao Chunlian Ye Yu Sun Ying Zhang Zhiyuan Zhong |
| author_sort | Huilan He |
| collection | DOAJ |
| description | Abstract The immunomodulation of the tumor microenvironment is critical for effective cancer immunotherapy, particularly for tumors that exhibit limited responses to conventional treatments. However, current immune agonists developed for tumor immunomodulation face several challenges, such as poor intratumoral retention, inadequate biocompatibility, and restricted cellular targets, which ultimately hamper their therapeutic efficacy and clinical application. In this study, a tumor‐adhesive chitosan‐tethered immune agonist construct (TACTIC) is introduced, which demonstrates good biocompatibility and robust immunostimulatory effects, enhancing the immunogenicity of tumor cells while simultaneously stimulating pro‐inflammatory responses in various immune cell populations. Mechanistic investigations reveal that TACTIC targets multiple signaling pathways, conferring it to effectively remodel the irradiated tumor microenvironment, improve tumor control on murine cancer models post‐radiotherapy, and elicit systemic immune responses with memory effects. The findings highlight the potential of TACTIC as a powerful macromolecular immune adjuvant, paving the way for its broader application in innovative cancer immunotherapies. |
| format | Article |
| id | doaj-art-8a982e29b89a497b8a0ffb2673ed6ff3 |
| institution | OA Journals |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-8a982e29b89a497b8a0ffb2673ed6ff32025-08-20T02:18:32ZengWileyAdvanced Science2198-38442025-04-011216n/an/a10.1002/advs.202414110Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer ImmunityHuilan He0Liang Liu1Yun Zheng2Jinlong Ji3Li Cao4Chunlian Ye5Yu Sun6Ying Zhang7Zhiyuan Zhong8College of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 ChinaCollege of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 ChinaCollege of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 ChinaBiomedical Polymers LaboratoryCollege of Chemistry, Chemical Engineering and Materials ScienceSoochow UniversitySuzhou 215123 ChinaCollege of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 ChinaBiomedical Polymers LaboratoryCollege of Chemistry, Chemical Engineering and Materials ScienceSoochow UniversitySuzhou 215123 ChinaBiomedical Polymers LaboratoryCollege of Chemistry, Chemical Engineering and Materials ScienceSoochow UniversitySuzhou 215123 ChinaCollege of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 ChinaCollege of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection Soochow University Suzhou 215123 ChinaAbstract The immunomodulation of the tumor microenvironment is critical for effective cancer immunotherapy, particularly for tumors that exhibit limited responses to conventional treatments. However, current immune agonists developed for tumor immunomodulation face several challenges, such as poor intratumoral retention, inadequate biocompatibility, and restricted cellular targets, which ultimately hamper their therapeutic efficacy and clinical application. In this study, a tumor‐adhesive chitosan‐tethered immune agonist construct (TACTIC) is introduced, which demonstrates good biocompatibility and robust immunostimulatory effects, enhancing the immunogenicity of tumor cells while simultaneously stimulating pro‐inflammatory responses in various immune cell populations. Mechanistic investigations reveal that TACTIC targets multiple signaling pathways, conferring it to effectively remodel the irradiated tumor microenvironment, improve tumor control on murine cancer models post‐radiotherapy, and elicit systemic immune responses with memory effects. The findings highlight the potential of TACTIC as a powerful macromolecular immune adjuvant, paving the way for its broader application in innovative cancer immunotherapies.https://doi.org/10.1002/advs.202414110cancer therapyimmune agonistimmunomodulationmulti‐targetsradiotherapy |
| spellingShingle | Huilan He Liang Liu Yun Zheng Jinlong Ji Li Cao Chunlian Ye Yu Sun Ying Zhang Zhiyuan Zhong Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity Advanced Science cancer therapy immune agonist immunomodulation multi‐targets radiotherapy |
| title | Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity |
| title_full | Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity |
| title_fullStr | Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity |
| title_full_unstemmed | Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity |
| title_short | Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity |
| title_sort | tumor adhesive chitosan derived multi immune agonist unleashes strong and durable anti cancer immunity |
| topic | cancer therapy immune agonist immunomodulation multi‐targets radiotherapy |
| url | https://doi.org/10.1002/advs.202414110 |
| work_keys_str_mv | AT huilanhe tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT liangliu tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT yunzheng tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT jinlongji tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT licao tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT chunlianye tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT yusun tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT yingzhang tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity AT zhiyuanzhong tumoradhesivechitosanderivedmultiimmuneagonistunleashesstronganddurableanticancerimmunity |